Article

The effect of AKT pathway inhibition on reversal of platinum resistance in ovarian cancer : a translational approach

2014-01-01

Abstract excerpt

Dysregulation of the phosphotidylinositol-3-kinase (PI3-kinase)/AKT signalling pathway is one of the most frequent mutational events in various human malignancies, including ovarian cancer. Increased PI3K/AKT activity in malignant cells is associated with resistance to chemotherapeutic agents. GSK2141795 is a potent pan-AKT kinase inhibitor, being developed for ovarian and other cancers. The aim of the present stu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e25b61ce-fb1f-5f2a-a906-e1ae4ea536ef
DOI: 10.25560/39596

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The effect of AKT pathway inhibition on reversal of platinum resistance in ovarian cancer : a translational approachDOI 10.25560/39596Read

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Semantic proximity Read

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum ResistanceSemantic proximity Read

Positron emission tomography imaging of platinum resistant ovarian cancer and drug modulationSemantic proximity Read

Targeting the DNA damage response network as a therapeutical strategy in ovarian and pancreatic cancersSemantic proximity Read

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.Semantic proximity Read

Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)Semantic proximity Read

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroSemantic proximity Read

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cellsSemantic proximity Read

[PI3K and mTOR pathway and molecular targeted agents].Semantic proximity Read

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Semantic proximity Read

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondSemantic proximity Read

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Semantic proximity Read